Correction to the Admission Document

Amirose London Holdings

28/07/2021 07:00

RNS Number : 6777G

Clarify Pharma PLC

28 July 2021

 

28 July 2021

Clarify Pharma PLC

("Clarify Pharma" or the "Company")

Correction to the Admission Document dated 11 June 2021

 

Clarify Pharma (AQSE: PSYC) has identified that the statement of Directors' interests set out in the Company's Admission Document dated 11 June 2021 ("Admission Document") was incorrect. The disclosure on page 47 of the original admission document should have stated that Patrick McBride owned 20,000,000 shares of the Company via Ontario Inc. and Nicholas Lyth owned 500,000 shares of the Company. There is no change to the stated amount of total shares outstanding. The disclosure in the admission document should be read with the above correction.

 

-END-

 

About Clarify Pharma

Clarify Pharma is an investment vehicle focusing on investing in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic-based substances. The Company looks to identify investment opportunities in the life sciences sector within the UK, Canada and other growing markets, with the objective of generating long-term capital growth and building investments in an R&D pipeline of companies which are discovering, developing, or deploying safe and evidence-based psychedelic inspired medicines and experiential therapies that alleviate mental health problems and enhance wellbeing.

Clarify Pharma is working to assemble a portfolio of companies that focus on the development of psychedelic inspired medicines and experiential therapies for human clinical trials under the supervision and strict adherence to the guidelines of the United Kingdom's MHRA, Canada's Health Canada as well as similar regulatory authorities in other jurisdictions where Clarify or its Investee Companies operate.

The Company's Directors have an established track record, experience and networks in the psychedelic, cannabinoid and media industries, to drive value creation.

For further information please contact:

Clarify Pharma
Jon Bixby
Executive Chairman
via Tancredi +44 207 887 7633
First Sentinel
Corporate Adviser
Brian Stockbridge
+44 7876 888 011
Tennyson Securities
Corporate Broker
Peter Krens
+44 207 186 9030
Tancredi Intelligent Communication
Media Relations
Catrina Daly
Emma Hodges
Salamander Davoudi
clarifypharma@tancredigroup.com
+44 7727 153 868
+44 7861 995 628
+44 7957 549 906

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NEXFFFSLDIIDFIL